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Abstract
Background: Ezetimibe specifically blocks the absorption of dietary and biliary cholesterol and plant sterols. 
Synergism of ezetimibe-statin therapy on LDL-cholesterol has been demonstrated, but data concerning the pleiotropic 
effects of this combination are controversial.
Objective: This open-label trial evaluated whether the combination of simvastatin and ezetimibe also results in a 
synergistic effect that reduces the pro-inflammatory status of pre-diabetic subjects.
Methods: Fifty pre-diabetic subjects were randomly assigned to one of 2 groups, one receiving ezetimibe (10 mg/day), 
the other, simvastatin (20 mg/d) for 12 weeks, followed by an additional 12-week period of combined therapy. Blood 
samples were collected at baseline, 12 and 24 weeks. RESULTS: Total cholesterol, LDL-cholesterol and apolipoprotein B 
levels decreased in all the periods analyzed (p < 0.01), but triglycerides declined significantly only after combined 
therapy. Both drugs induced reductions in C-reactive protein, reaching statistical significance after combining 
ezetimibe with the simvastatin therapy (baseline 0.59 ± 0.14, simvastatin monotherapy 0.48 ± 0.12 mg/dL and 0.35 ± 
0.12 mg/dL, p < 0.023). Such a reduction was independent of LDL-cholesterol change. However, mean levels of TNF-α 
and interleukin-6 and leukocyte count did not vary during the whole study.
Conclusion: Expected synergistic lowering effects of a simvastatin and ezetimibe combination on LDL-cholesterol, 
apolipoprotein B and triglycerides levels were confirmed in subjects with early disturbances of glucose metabolism. 
We suggest an additive effect of this combination also on inflammatory status based on the reduction of C-reactive 
protein. Attenuation of pro-inflammatory conditions may be relevant in reducing cardiometabolic risk.
Title/ID of trial registration: Effect of simvastatin and ezetimibe on lipid and inflammation/NCT01103648.
Introduction
Long-term benefits of statins on primary and secondary
prevention of cardiovascular events have been consis-
tently shown in several populations [1-3]. It has been
demonstrated that, with particular regard to subjects at
high risk, the lower LDL-cholesterol levels, the lower the
incidence of cardiovascular outcomes [4,5]. Evidence
indicates that the beneficial effects of statins can be
attributed to their lipid-lowering ability as well as to addi-
tional benefits. The so-called pleiotropic effects on low
grade inflammation status have been described in subsets
of subjects with different cardiovascular profiles [6,7].
The most common inflammatory marker used in clinical
practice is the high-sensitivity C-reactive protein (CRP)
level, but a number of others have also been investigated.
Disturbances of glucose metabolism accompanied by
insulin resistance are pro-inflammatory conditions which
may accelerate atherosclerotic process. Diabetic popula-
tions are considered at high cardiovascular risk and strict
control of lipoprotein concentrations is recommended
[8,9]. Several recent studies showed the efficacy of statins
on primary and secondary prevention of cardiovascular
events in diabetic populations [3,10,11]. The goal of 100
mg/dl for LDL-cholesterol may be too high for subjects at
very high risk for whom a target of 70 mg/dL has been
suggested [8,9]. To achieve this goal, high statin doses
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Given that statin monotherapy may be insufficient for the
desirable reduction in LDL levels, a combination of lipid-
lowering agents has become frequent in clinical practice.
In particular, statin and ezetimibe combination has been
shown to be very effective in reducing total and LDL-
cholesterol levels [12,13].
Ezetimibe is a specific cholesterol absorption inhibitor
that acts at the brush border of the small intestine, block-
ing the absorption of dietary and biliary cholesterol and
plant sterols, resulting in intracellular cholesterol deple-
tion via the Niemann-Pick C1-like transporter [14]. Add-
ing ezetimibe to statin therapy induces a 15% reduction in
LDL levels compared with only 6% achieved by doubling
the dose of statins [15,16]. Data concerning the pleiotro-
pic effects of this combination are controversial. One
study, in which CRP level was used as the inflammatory
marker, found that a combination of simvastatin and
ezetimibe produced an incremental effect in lowering
CRP, independently of the improvement in lipoprotein
concentrations [17]. Although few studies have con-
firmed this finding [18-20], as far as we know, data
regarding simvastatin-ezetimibe combination induced-
changes in serum interleukin-6 (IL-6) and tumor necrosis
factor alpha (TNF-α) levels are lacking. We tested the
hypothesis that this combination would induce improve-
ment in inflammatory status, as reflected by leukocyte
count and CRP, IL-6 and TNF-α levels.
Therefore, this study evaluates whether the combina-
tion of lipid-lowering effects of low-to-moderate dose of
simvastatin and ezetimibe also results in a synergistic
effect that reduces the pro-inflammatory status of pre-
diabetic subjects with mild-to-moderate hypercholester-
olemia.
Subjects and Methods
Participants were selected from the Federal University of
São Paulo outpatient clinics. The study was approved by
the institutional ethical committee and all participants
were provided with written informed consent. Details on
the characteristics of the participants and study protocol
were previously described [21]. Briefly, eligible subjects
were men and women, aged from 18 to 75 years, with a
body mass index (BMI) ranging from 25 to 40 kg/m2 and
pre-diabetes (impaired glucose tolerance or impaired
fasting glucose). Entry criteria required triglyceride levels
≤ 350 mg/dL and LDL-cholesterol ≤ 200 mg/dL, stable
blood pressure and no evidence of cardiovascular, hepatic
or renal diseases. Subjects were not taking anti-inflam-
matory agents or others interfering with lipid or glucose
metabolism. Eligible participants were recruited from
June 2005 to May 2006.
In this open-label uncontrolled clinical trial, 290 sub-
jects with weight excess, with or without family history of
diabetes, were screened for the interventional protocol
and 50 with impaired glucose tolerance (IGT) or
impaired fasting glucose (IFG) were randomly assigned to
2 groups that would receive ezetimibe 10 mg/day (n = 25)
or simvastatin 20 mg/day (n = 25), preceded by a 2-week
run-in period. Simple randomization was applied throw-
ing a dice for each participant to define the initial therapy.
Monotherapies were maintained for 12 weeks; thereafter
the drugs were combined in each group for an additional
12-week period. All participants received individual
counseling for a healthy lifestyle and had monthly visits.
Treatment was to be discontinued prematurely if
transaminases exceeded 3 times the upper limit of refer-
ence or creatine phosphokinase (CPK) 10 times, but no
subject met these criteria. One of the ezetimibe group
dropped out due to non-compliance. Sample size and
power to detect differences with the lipid-lowering agents
were calculated based on the reduction in LDL-choles-
terol concentration. The power to detect differences with
the interventions was 0.75. In addition to expected reduc-
tions in lipid concentrations, inflammatory markers
(CRP, IL-6 and TNF-α) changes were also considered out-
comes of the interventions.
Baseline, 12-week and 24-week blood samples were
drawn in the morning, after a 12-hour fast, for glucose,
lipid profile, including apolipoprotein A-I and B, leuko-
cyte count and inflammatory markers were made. A
LDL-cholesterol goal of 100 mg/dL was used in the pres-
ent study [8,22].
Laboratory analysis
Plasma glucose, transaminases, CPK and creatinine were
determined by routine methods. Serum lipid levels (total
cholesterol, HDL-cholesterol, and triglycerides) were
analyzed by commercially available tests (Roche Diagnos-
tics GmbH, Mannheim, Germany). Blood samples were
stored at -20°C until determinations of apolipoproteins
and inflammatory markers. Apolipoprotein A-I and B
were measured by immunoturbidimetry (Olympus Life
and Material Science Europa GmbH, Lismeeham, Ire-
land), with an intra-assay coefficient of variability (CV) of
1.26-1.30% and 0.93-1.17% respectively, and an inter-
assay CV of 1.43-1.55% and 1.10-1.46%, respectively.
High-sensitivity CRP (Immulite - DPC, Los Angeles, CA,
USA), TNF-α and IL-6 (Immulite - Euro/DPC, Llanberis,
Gwynedd, UK) were determined by chemiluminescent
immunometric assay. The sensitivity of CRP assay was
0.01 mg/dL (intra-assay CV 4.2-6.4% and inter-assay CV
4.8-10%), of TNF-α assay 1.7 pg/mL (intra-assay CV 2.6-
3.6%, inter-assay CV 4.0-6.5%) and of IL-6 assay was 2.0
pg/mL (intra-assay CV 3.5-6.2%, inter-assay CV 5.1-
7.5%).
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Data were expressed as mean values and standard errors
or deviations. Unpaired Student's t test was used to com-
pare groups at baseline and chi-square to assess differ-
ences between qualitative data. One-way ANOVA for
repeated measures was used to evaluate the effect of
drugs over time and to compare data between groups of
subjects according to the type of therapy. In such analysis,
pairwise contrasts were made by comparing least-square
mean estimates; p-values were adjusted for multiple com-
parisons using the Bonferroni Holm method. A signifi-
cant p-value (p < 0.05) signalizes the existence of a
statistical difference, considering that the alpha value of
5% was divided by the number of comparisons for each
variable. If a difference in a given variable was detected
along the time, 3 comparisons (baseline versus monother-
apy, baseline versus combination and monotherapy versus
combination) were performed, considering that the effect
was significant when p values was < 0.05 divided by 3
(significant p value < 0.017). Correlation between vari-
ables was tested by the Pearson coefficient. This coeffi-
cient was also employed to assess whether changes in
variables over time were correlated. Data analysis was
performed using Statistical Analysis System software,
version 8.2 (SAS Institute, Cary, NC).
Results
Main baseline characteristics of the subjects are
described in Table 1. Except for higher mean fasting
plasma glucose for the group which started monotherapy
with simvastatin, groups were similar regarding sociode-
mographic data, frequency of hypertension, mean values
of blood pressure and biochemical variables.
Only for those subjects who started the protocol with
ezetimibe (ezetimibe group), did the mean values of BMI
and abdominal circumference decrease significantly after
monotherapy, but not following the combination therapy
(Table 2). No variation in these parameters was observed
for the simvastatin group.
Total cholesterol, LDL-cholesterol and apolipoprotein
B had similar profiles during follow-up for both groups
(Figure 1). Significant declines were observed in all the
periods analyzed, as shown in Table 2. A combination of
simvastatin and ezetimibe was more effective than iso-
lated drugs in reducing lipid levels. However, simvastatin
in isolation showed a greater improvement in total cho-
lesterol, LDL-cholesterol and apolipoprotein B than did
ezetimibe monotherapy. Thirty-five percent of the sub-
jects treated with ezetimibe monotherapy reached the
goal of 100 mg/dl, as did 72% with simvastatin monother-
apy, and 91% with a combination of drugs. Similar per-
cent increments were verified when apolipoprotein B
levels were considered. Significant decreases in triglycer-
ide levels were found with the combination therapy, but
no significant changes were observed with monothera-
pies. HDL-cholesterol or apolipoprotein A-I concentra-
tions did not change throughout the whole protocol.
The effects of ezetimibe and simvastatin monothera-
pies and of the combination of drugs on inflammatory
parameters are shown in Table 2. Decreases in CRP and
IL-6 induced by ezetimibe therapy were not significant.
In the simvastatin group, CRP reduces significantly and
the decline was accentuated following the combined ther-
Table 1: Baseline characteristics of the participants.
Ezetimibe
n = 24
Simvastatin
n = 25
p-value
Women (%) 79 76
Caucasians (%) 41 47
Smoking (%) 4 12
Hypertension (%) 92 80
Age (years) 53.4 ± 9.3 53.1 ± 8.1 0.893
Body mass index (kg/m2) 33.1 ± 4.5 31.9 ± 3.4 0.333
Systolic blood pressure (mmHg) 129.3 ± 16.2 124.0 ± 20.4 0.325
Diastolic blood pressure (mmHg) 83.3 ± 8.7 81.6 ± 11.5 0.575
Total cholesterol (mg/dL) 237.4 ± 43.2 214.4 ± 39.7 0.058
LDL-cholesterol (mg/dL) 145.9 ± 39.9 129.4 ± 36.8 0.139
HDL-cholesterol (mg/dL) 56.1 ± 13.7 53.1 ± 11.5 0.408
Triglycerides (mg/dL) 176.8 ± 85.4 160.0 ± 65.5 0.443
Fasting plasma glucose (mg/dL) 104.3 ± 6.7 110.0 ± 11.7 0.041
Data are expressed in number of subjects or mean ± standard deviation.
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relation with changes in LDL-cholesterol levels.
As far as inflammatory markers are concerned, baseline
values of CRP levels were positively correlated to leuko-
cyte count (r = 0.55, p < 0.001), IL-6 (r = 0.25, p < 0.05),
TNF-α (r = 0.24, p = 0.05), and abdominal circumference
(r = 0.24, p = 0.05). Leukocyte count was also correlated
to abdominal circumference (r = 0.27, p < 0.05). Table 2
shows that both drugs induced reductions in CRP, reach-
ing statistical significance only after the addition of
ezetimibe to the simvastatin therapy (Figure 1). However,
no significant change was observed in mean levels of
TNF-α, IL-6 and leukocyte count throughout the whole
study. A significant higher number of subjects treated
with the combination of ezetimibe and simvastatin
achieved a CRP concentration less than 0.2 mg/dL when
compared with those undergoing simvastatin monother-
apy (64% vs. 48%, respectively, p < 0.05).
Discussion
This study provides further proof of the role of the com-
bination of 2 different classes of lipid-lowering agents in
improving the atherogenic lipid profile of pre-diabetic
subjects. The combination of simvastatin and ezetimibe
resulted in greater reductions in LDL-cholesterol, apoli-
poprotein B and triglyceride levels when compared to
both monotherapies. The long-term control of lipid pro-
file has been consistently associated with a decrease in
cardiovascular morbidity and mortality of subjects with
or without glucose metabolism disturbances [1-3,10,11],
but more recent evidence suggests that cardiovascular
protection may be also attributed to the attenuation of
Table 2: Anthropometry, biochemical and inflammatory variables in different moments of the study protocol.
Baseline Monotherapy Combination p value
Ezetimibe group
Body mass index (kg/m2) 33.0 ± 0.9 32.4 ± 0.9* 32.4 ± 1.0* 0.002
Abdominal circumference (cm) 102.9 ± 2.1 100.6 ± 2.2* 101.4 ± 2.2 0.010
Total cholesterol (mg/dL) 237.4 ± 8.8 197.0 ± 7.2* 147.8 ± 6.4*# <0.001
LDL-cholesterol (mg/dL) 145.9 ± 8.2 112.5 ± 6.4* 66.6 ± 4.8*# <0.001
HDL-cholesterol (mg/dL) 56.1 ± 2.8 55.4 ± 2.1 56.9 ± 2.5 0.855
Triglycerides (mg/dL) 176.8 ± 17.4 145.4 ± 15.9* 121.4 ± 11.3* <0.001
Apolipoprotein B (mg/dL) 115.6 ± 5.0 93.3 ± 4.6* 66.9 ± 3.7*# <0.001
Apolipoprotein A-I (mg/dL) 157.7 ± 5.3 153.2 ± 5.0 151.1 ± 6.3 0.149
Leucocytes (×103 cel/mm3) 5.83 ± 0.26 6.07 ± 0.25 6.00 ± 0.31 0.394
C reactive protein (mg/dL) 0.57 ± 0.12 0.46 ± 0.09 0.44 ± 0.14 0.452
Interleukin-6 (pg/mL) 3.1 ± 0.5 2.5 ± 0.3 2.5 ± 0.2 0.286
TNF-α (pg/mL) 8.8 ± 3.2 5.9 ± 0.3 6.1 ± 0.2 0.229
Simvastatin group
Body mass index (kg/m2) 31.9 ± 0.7 31.8 ± 0.7 31.6 ± 0.8 0.660
Abdominal circumference (cm) 101.8 ± 1.6 101.8 ± 1.6 101.3 ± 1.9 0.999
Total cholesterol (mg/dL) 214.4 ± 7.9 168.1 ± 8.3* 139.5 ± 7.0*# <0.001
LDL-cholesterol (mg/dL) 129.4 ± 7.4 84.8 ± 7.0* 62.4 ± 5.5*# <0.001
HDL-cholesterol (mg/dL) 53.1 ± 2.3 53.2 ± 2.4 54.5 ± 2.5 0.885
Triglycerides (mg/dL) 160.0 ± 13.1 150.5 ± 17.3 112.6 ± 9.7*# <0.001
Apolipoprotein B (mg/dL) 103.8 ± 4.8 77.9 ± 4.5* 63.3 ± 4.0*# <0.001
Apolipoprotein A-I (mg/dL) 154.9 ± 3.8 152.1 ± 4.2 152.5 ± 4.7 0.375
Leucocytes (×103 cel/mm3) 5.91 ± 0.36 5.87 ± 0.40 5.91 ± 0.44 0.924
C reactive protein (mg/dL) 0.59 ± 0.14 0.48 ± 0.12 0.35 ± 0.12*# 0.023
Interleukin-6 (pg/mL) 2.8 ± 0.3 2.3 ± 0.2 2.5 ± 0.2 0.146
TNF-α (pg/mL) 6.1 ± 0.2 6.2 ± 0.2 6.6 ± 0.4 0.261
Data are expressed in means ± standard error.
* p < 0.017 versus baseline
# p < 0.017 versus monotherapy
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intolerance is a major cardiovascular risk factor and a
pro-inflammatory condition, a therapeutic approach able
to reduce lipids and inflammatory markers should be of
particular interest [23].
Statins are the most important lipid-lowering agents
used in clinical practice for patients at different levels of
cardiovascular risk. Despite their efficacy, almost fifty
percent of at-risk patients do not achieve LDL-cholesterol
goals according to the European Second Joint Task Force
and the US National Cholesterol Education Program
Adult Treatment Panel III guidelines [8,22,24]. Since
monotherapy may be ineffective in reaching the target,
more options are desirable to optimize the management
of hypercholesterolemic subjects. In the present study,
the percentage of those reaching a LDL-cholesterol goal
of 100 mg/dl increased from 72% induced by statin
monotherapy to 91% following the simvastatin-ezetimibe
combination.
In addition to the improvement in lipid profile, syner-
gistic anti-inflammatory effects of the 2 agents used in
the present study are suggested by our findings on serum
concentrations of CRP, an established inflammatory
marker associated with cardiovascular risk [25,26]. It is
known that the beneficial effects of statins on cardiovas-
cular system go beyond decreasing cholesterol levels.
Atherosclerotic process should also be delayed by dimin-
ishing inflammation, which is translated into lower
inflammatory markers, better anti-thrombotic activity
and endothelial function. However, it was not demon-
strated whether anti-inflammatory effects of statins per se
would help to postpone diabetes mellitus development.
Some investigators have proposed that CRP concentra-
tion may be the strongest predictor of cardiovascular
events when compared to other risk factors, but this is
still a matter of controversy [27,28]. Achieving lower lev-
els of CRP with lipid-lowering agents may have an addi-
tional benefit on the cardiovascular system of subjects at
elevated risk such as pre-diabetic ones. Subjects included
in the present study had normal or slight elevation of
cholesterol levels. It was not known if the use of statin to
reduce CRP in normocholesterolemic subjects was able
to improve cardiovascular outcomes. Recently, an analy-
sis of 15,548 initially healthy men and women participat-
ing in the JUPITER trial corroborated this statement [29].
CRP concentration was predictive of cardiovascular
event rates irrespective of the lipid endpoint use. The
Figure 1 Lipid profile and C reactive protein concentration of subjects initially receiving ezetimibe and simvastatin at baseline, on mono-
therapy and with combined therapy.
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achieved normal LDL-cholesterol and CRP < 1 mg/L.
Ezetimibe added to simvastatin therapy provoked a sig-
nificant improvement in CRP levels and such an effect
was independent of LDL-cholesterol decrease. The ability
of statin therapy to reduce CRP has been reported, but a
synergistic effect of the combination with ezetimibe has
been less frequently described [17-20]. Sager et al have
demonstrated that ezetimibe 10 mg plus simvastatin is
more efficient in lowering the serum concentration of
CRP than simvastatin in isolation, in all doses analyzed
(10 till 80 mg) independently of the LDL-cholesterol fall
[17,18]. In the VYTAL study [19], the fixed combination
ezetimibe/simvastatin reduced CRP more than atorvasta-
tin monotherapy. Taking into consideration all the doses
used, the combination achieved both LDL and CRP goals
in a markedly higher number of patients than did atorvas-
tatin monotherapy. In our study, more subjects treated
with the combination of ezetimibe and simvastatin
achieved a CRP value less than 0.2 mg/dl when compared
with those undergoing simvastatin monotherapy (64% vs.
48%, respectively). In agreement, Pearson et al [20], using
the same fixed combination of ezetimibe/simvastatin 10/
20 mg, found a similar decrease of 30% in CRP levels.
Few studies are available to investigate the attenuation
of pro-inflammatory status based on leukocytes count
and IL-6 and TNF-α levels. Some studies suggest that sta-
tins are able to reduce IL-6 and TNF-α levels [23,30]. In a
randomized, double-blind, placebo-controlled clinical
trial, conducted on 50 subjects, daily administration of 40
mg of simvastatin provoked significant decreases in IL-6
and TNF-α concentrations [23]. In another study, our
group found that a lower dose of simvastatin (20 mg/day),
but over a longer period (16 weeks), was able to decrease
IL-6 levels significantly [30]. As far as we know, no study
focusing on the responses of these inflammatory markers
to the combination of statin and ezetimibe is available. In
the present study, no change was detected regarding IL-6
or TNF-α levels and leukocytes count.
A weakness of our study is the sample size. The relative
small sample size associated with the large range of varia-
tion observed in these parameters may have limited to
detect statistical differences. In fact, our sample size was
not calculated for comparisons between the inflamma-
tory markers. In addition, a lower statin dose and shorter
follow-up period could be contributing to the lack of IL-6
and TNF-α responses in our study. Another explanation
could be based on the fact that IL-6 and TNF-α actions
are mainly at autocrine and paracrine levels [31] and cir-
culating measurements of cytokines may be inappropri-
ate to detect variations at those sites.
In summary, we have confirmed the synergistic lower-
ing effect of low-to-moderate simvastatin and ezetimibe
combination on LDL-cholesterol, apolipoprotein B and
triglycerides levels in pre-diabetic subjects. As far as
inflammatory markers are concerned, a favorable effect,
independently of LDL-cholesterol change, is suggested by
the CRP reduction, but not by other parameters. Other
prospective studies, including larger samples and higher
medication doses, may be necessary to draw conclusions
about the role of statins and ezetimibe combination on
pro-inflammatory profile and long-term benefits for car-
diometabolic risk.
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